Check Credit Score
Check Credit Score
HomeNewsWorld

Coronavirus pandemic | SARS-Cov-2 has changed form 11 times so far, ICMR study finds

About 45.7 percent of the Indian samples that were studied were found to be type A2a, which evolved from its ancestral type O first found in Wuhan, China.

May 26, 2020 / 09:00 AM IST
Representative image

Representative image

The most prominent type of SARS-Cov-2 from the novel coronavirus family that causes COVID-19, has mutated at least 11 times so far - Indian scientists have said.

Researchers at the National Institute of Biomedical Genomics have studied the genome sequencing data from 3,636 patients across 55 countries, including 21 samples from India.

A report in The BusinessLine cites these researchers from the Indian Council of Medical Research (ICMR) institute in West Bengal as saying that the dominant virus that had evolved in February and March was of the A2a type.

When a virus mutates, it changes form to create genetic diversity. A virus changing its forms or modifying itself is key to its survival. The more it mutates, the more it is likely to reproduce itself.

The report, citing a study published in the Indian Journal of Medical Research, further suggests that type A2a, consisting of 1,848 (51 percent) of the samples, evolved from its ancestral type O - first found in Wuhan, China.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Among the Indian samples, 16 (45.7 percent) were of A2a type, 13 (37.1 percent) were A3, five (14.3 percent) were O and just one was of B type (2.9 percent).

The study has reportedly recommended large scale genomes sequencing of host patients in India to help identify regional and ethnic variation in viral composition.

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

It was earlier reported that the A2a type had become dominant and spread across geographical regions.

According to another study, the A2a mutation of the novel coronavirus is highly efficient in entering human lung cells in large numbers. The previous SARS-CoV, which had emerged in 2010 and infected over 8,000 and killed 800, was also efficient in attacking human lung cells, but it was not as adept as A2a.

It was also reported that a mutated strain of SARS-Cov-2, which had begun spreading in Europe in February and then in the United States and Canada, become the dominant form of the virus worldwide by March.

Click here for Moneycontrol’s full coverage of the novel coronavirus pandemic

Moneycontrol News
first published: May 26, 2020 08:50 am

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347